662 related articles for article (PubMed ID: 25342080)
1. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
Schaeffer E; Pilotto A; Berg D
CNS Drugs; 2014 Dec; 28(12):1155-84. PubMed ID: 25342080
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for levodopa-induced dyskinesia.
Al Dakheel A; Beaulieu-Boire I; Fox SH
Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568
[TBL] [Abstract][Full Text] [Related]
3. Current treatment and future prospects of dopa-induced dyskinesias.
Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
[TBL] [Abstract][Full Text] [Related]
4. Non-dopaminergic treatments for motor control in Parkinson's disease.
Fox SH
Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
[TBL] [Abstract][Full Text] [Related]
5. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
6. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Duty S
CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
[TBL] [Abstract][Full Text] [Related]
7. Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
Dragašević-Mišković N; Petrović I; Stanković I; Kostić VS
Expert Opin Pharmacother; 2019 Feb; 20(2):219-230. PubMed ID: 30411647
[TBL] [Abstract][Full Text] [Related]
8. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
AlShimemeri S; Fox SH; Visanji NP
Expert Opin Emerg Drugs; 2020 Jun; 25(2):131-144. PubMed ID: 32366130
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
Cheshire PA; Williams DR
J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
[TBL] [Abstract][Full Text] [Related]
12. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
[TBL] [Abstract][Full Text] [Related]
13. Amantadine Extended-Release (GOCOVRI
Paik J; Keam SJ
CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide, a new player in L-DOPA-induced dyskinesia?
Del-Bel E; Padovan-Neto FE; Bortolanza M; Tumas V; Aguiar AS; Raisman-Vozari R; Prediger RD
Front Biosci (Elite Ed); 2015 Jan; 7(1):168-92. PubMed ID: 25553372
[TBL] [Abstract][Full Text] [Related]
15. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Thanvi B; Lo N; Robinson T
Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
[TBL] [Abstract][Full Text] [Related]
16. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
17. Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
Kwon DK; Kwatra M; Wang J; Ko HS
Cells; 2022 Nov; 11(23):. PubMed ID: 36496996
[TBL] [Abstract][Full Text] [Related]
18. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
[TBL] [Abstract][Full Text] [Related]
19. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
20. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]